Why the study?
Does adjuvant Epirubicin / Cyclophosphamide chemotherapy affect erythrocyte aggregation, plasma viscosity, and hematocrit in women with stage II breast cancer?
Does adjuvant Epirubicin / Cyclophosphamide chemotherapy affect erythrocyte aggregation, plasma viscosity, and hematocrit in women with stage II breast cancer?
Answers are grounded in this paper and cite their sources.
Small observational study leaves open whether adjuvant EC alters hemorheology in stage II breast cancer; larger prospective trials needed.
We examined 43 women with stage II breast cancer receiving adjuvant Epirubicin / Cyclophosphamid chemotherapy. Preoperatively and before each of six cycles of chemotherapy erythrocyte aggregation (stasis and low shear), plasma viscosity, hematocrit,
No takes yet. Share an insight, caveat, or question.
Tempelhoff et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: